general news

Asahi Kasei to acquire U.S.-based biopharma CDMO Bionova Scientific

Asahi Kasei to acquire U.S.-based biopharma CDMO Bionova Scientific
Asahi Kasei to acquire U.S.-based biopharma CDMO Bionova Scientific

Asahi Kasei Medical has reportedly planned to acquire Bionova Scientific LLC, a U.S.-based company that provides GMP-compliant contract manufacturing services and contract process development services to biopharma companies.

The bioprocess business of Asahi Kasei is one of the growth engines of the Asahi Kasei Group. Apart from manufacturing and selling bioprocess equipment and Planova™ filters, Asahi Kasei has been expanding the business into biosafety contract testing with various acquisitions. These include Virusure Forschung und Entwicklung GmbH, an Austria-based provider of viral safety testing services acquired in 2019, followed by the acquisition of Bionique Testing Laboratories LLC in 2021.

The process development abilities of Bionova Scientific are well known in the industry and it has an extensive track record in complex next-gen antibody drugs, which are generally difficult to manufacture. Its GMP manufacturing plant has advanced equipment like single-use bioreactors that comply to fulfill surging demand steered by the proliferation of the antibody drug industry and a steep rise in the number of biopharmaceuticals.

The acquisition of Bionova Scientific will allow Asahi Kasei to include a biopharma contract development and manufacturing organization (CDMO) in its bioprocess business.

As GMP manufacturing and process development operations are key to the overarching success of the businesses of biopharma consumers, the ability to offer an extensive range of critical knowledge-driven services to biopharma consumers will enable Asahi Kasei to grow its bioprocess business through effective industrial service and a wider customer reach.

Through its provision of reliable and innovative products and services, Asahi Kasei Medical intends to contribute to enhanced safety and efficient production of biotherapeutics and to further steer the growth of the Group’s healthcare sector.

It is worth noting that next-gen antibody-based drugs are different from traditional antibody-based drugs based on the sophistication of the action mechanism and the degree of complexity. The closure of the acquisition is subject to the reception of necessary regulatory approvals.

Source credit:

https://www.businesswire.com/news/home/20220417005039/en/Asahi-Kasei-Medical-to-Acquire-Bionova-Scientific-U.S.-based-Biopharmaceutical-CDMO

About the author

Vinisha Joshi

Vinisha Joshi

Despite graduating with an engineering degree in electronics and communication, Vinisha Joshi chose the road less travelled, and decided to pursue her career in content writing . Currently, she pens down articles for cuereport.com and a few other distinguished news platforms, pertaining to business and finance.